Related Experiment Video

Updated: May 3, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

1.8K

Potential approaches to reverse or repair renal fibrosis

Desiree Tampe1, Michael Zeisberg1

  • 1Department of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Robert Koch Straße 40, 37075 Göttingen, Germany.

Nature Reviews. Nephrology
|February 12, 2014
PubMed

Insights

Researchers are exploring ways to reverse chronic kidney disease (CKD) by targeting fibrosis. Promising antifibrotic therapies are being tested in clinical trials for kidney disease and other fibrotic conditions.

Area of Science:

  • Nephrology
  • Fibrosis Research
  • Translational Medicine

Background:

  • Chronic kidney disease (CKD) prevalence is increasing globally.
  • A significant unmet need exists for effective antifibrotic therapies in clinical practice.
  • Fibrosis is a common pathway in CKD progression and other organ damage.

Purpose of the Study:

  • To discuss therapeutic concepts for inhibiting or reversing chronic kidney injury.
  • To review leading candidate antifibrotic drugs for clinical use.

Main Methods:

  • Review of experimental models of CKD with antifibrotic potential.
  • Analysis of clinical trials assessing antifibrotic compounds.
  • Identification of targeted pathways including TGF-β, PI3K, chemokines, and microRNAs.

Main Results:

  • Experimental models show promise for effective antifibrotic treatment in CKD.
  • Multiple antifibrotic compounds are under investigation in clinical trials.
  • Targeting various fibrotic pathways offers therapeutic potential.

Conclusions:

  • Therapeutic strategies targeting fibrotic pathways are emerging for CKD.
  • Antifibrotic drug development is advancing towards clinical application.
  • Inhibiting or reversing kidney fibrosis is a key goal in nephrology research.

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Microdissection of Primary Renal Tissue Segments and Incorporation with Novel Scaffold-free Construct Technology09:00

Microdissection of Primary Renal Tissue Segments and Incorporation with Novel Scaffold-free Construct Technology

Published on: March 27, 2018

6.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
527
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
2.2K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.3K